The article discusses the potential impact of President Donald Trump's proposed 25% tariffs on foreign drugs, which could devastate the UK pharmaceutical industry, particularly giants like GlaxoSmithKline and AstraZeneca. With the US being their largest market, accounting for 40% of AstraZeneca's products, the UK government and pharmaceutical executives are racing to find exemptions. The article emphasizes the precarious nature of international trade negotiations and their potential consequences, with concerns about drug shortages being raised by company leaders.
Pharmaceutical bosses and the government are racing to stop Donald Trump slapping tariffs on medicines in a move that would significantly impact Britain's multi-billion pound industry.
America is the firms' largest market, with 40 per cent of all AstraZeneca products, worth more than 20 billion, exported to the US.
Weâre all just reacting to whatever comes out of the White House but I canât see a world where we wouldnât want to protect one of our biggest export markets.
The tariff could lead to medicine shortages, according to Johnson & Johnson boss Joaquin Duato.
Collection
[
|
...
]